CEPI Partners With Lemonex to Advance mRNA Vaccine Delivery
Lemonex announces approval of IND application for mRNA-DegradaBALL vaccine, LEM-mR203, phase 1 clinical trial
Lemonex, mRNA-DegradaBALL vaccine LEM-mR203 clinical phase 1 trial IND submission
Lemonex, IVI Exchange MOU on Joint Vaccine Development
SEOUL, South Korea--(BUSINESS WIRE)--Lemonex Inc., a biotechnology company pioneering messenger RNA (mRNA) and siRNA therapeutics based on novel nanoparticle drug delivery system announced on the 19th of April that The Ministry of Food and Drug Safety (MFDS) has approved the Investigational New Drug (IND) for siRNA gene therapy LEM-S401 with their nano-drug delivery platform, DegradaBALL® on 15th of April.